Antitumor effect of lung cancer vaccine with umbilical blood dendritic cells in reconstituted SCID mice

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 3, 2008, Pages 321-331

  Lin, Ping ^a   Lu, Yan Rong ^a   Zhang, Jie ^a   Wei, Yu Quan ^a   Wang, Xiu Jie ^a   Li, Sheng Fu ^a   Wang, Qi ^a   Xiong, Zhu Juan ^a   Ning, Qi Zhi ^a   Lei, Song ^a   Mao, Yong Qiu ^a   Cheng, Jing Qiu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antitumor effect; Lung cancer; Reconstituted SCID mice; Umbilical blood dendritic cell; Vaccine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CANCER VACCINE; CD3 ANTIGEN; CD83 ANTIGEN; DENDRITIC CELL VACCINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; LYMPHOTOXIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 4; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; T6 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LYSATE; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LUNG CANCER; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; UMBILICAL CORD BLOOD;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULINS; INTERLEUKIN-6; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; LYMPHOTOXIN-ALPHA; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; UMBILICAL VEINS;

EID: 46449107872     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0463     Document Type: Article

References (35)

1. Moser M, Murphy KM. Dendritic cell regulation of TH1-Th2 development. Nat Immunol 2000;1:199.
2. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255.
3. Biragyn A, Kwak LW. Designer cancer vaccines are still in fashion. Nat Med 2000;6:966.
4. Jackson SH, Yu CR, Mahdi RM, et al. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol 2004;172:2307.
5. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233.
6. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162:168.
7. Spiotto MT, Fu YX, Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol 2003;15:725.
8. Sandler AD, Chihara H, Kobayashi G, et al. CpG Oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 2003;63:394.
9. Jackson SH, Alicea C, Owens JW, et al. Characterization of an early dendritic cell precursor derived from murine lineage-negative hematopoietic progenitor cells. Exp Hematol 2002;30:430.
10. Winzler C, Rovere P, Rescigno M, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997;185:317.
11. Lin P, Azusa A, Okada A, et al. Dramatic increase of telomerase activity during dendritic cell differentiation and maturation. J Leukoc Biol 2003;74:270.
12. Martinez-Jaramillo G, Flores-Guzman P, Montesinos JJ, et al. In vitro proliferation and expansion of hematopoietic progenitors present in mobilized peripheral blood from normal subjects and cancer patients. Stem Cells 2004;13:382.
13. Markowicz S, Niedzielska J, Kruszewski M, et al. Nonviral transfection of human umbilical cord blood dendritic cells is feasible, but the yield of dendritic cells with transgene expression limits the application of this method in cancer immunotherapy. Acta Biochim Pol 2006;53:203.
14. Kim YJ, Brutkiewicz RR, Broxmeyer HE. Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells. Blood 2002;100: 3253.
15. Tse W, Laughlin M. Cord blood transplantation in adult patients. Cytotherapy 2005;7:228.
16. Cohen Y, Nagler A. Umbilical cord blood transplantation - how, when and for whom? Blood Rev 2004;18:167.
17. Barker JN, Wagner JE. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 2003;3:526.
18. Rauscher M. Tumor-infiltrating immune cells may control early metastasis of colorectal cancer. N Engl J Med 2005;353:2640.
19. Wang P, Munger CM, Joshi AD, et al. Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Res Treat 2004;83:15.
20. Oehen S, Brduscha-Riem K, Oxenius A, et al. A simple method for evaluating the rejection of grafted spleen cells by flow cytometry and tracing adoptively transferred cells by light microscopy. J Immunol Methods 1997;207:33.
21. Sjaheim T, Halstensen TS, Lund MB, et al. Airway inflammation in aluminium potroom asthma. Occup Environ Med 2004;61:779.
22. Waeckerle-Men Y, Scandella E, Uetz-Von Allmen E, et al. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly (lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods 2004;287:109.
23. Yuchen D, Ping L, Jie Z, et al. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Tissue Antigens 2006;67:368.
24. Lundqvist A, Nagata T, Kiessling R, et al. Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). Cancer Immunol Immunother 2002;51:139.
25. Meltzer U, Goldblatt D. Pneumococcal polysaccharides interact with human dendritic cells. Infect Immun 2006;74:1890.
26. Majewska M, Szczepanik M. Matrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cells. J Virol 2006;80:2194.
27. Gervassi A, Alderson MR, Suchland R, et al. Differential regulation of inflammatory cytokine secretion by human dendritic cells upon Chlamydia trachomatis infection. Infect Immun 2004;72:7231.
28. Perez L, Shurin MR, Collins B, et al. Comparative analysis of CD1a, S-100, CD83, and CD11c human dendritic cells in normal, premalignant, and malignant tissues. Histol Histopathol 2005;20:1165.
29. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005;83:451.
30. Dallal RM, Christakos P, Lee K, et al. Paucity of dendritic cells in pancreatic cancer. Surgery 2000:131:135.
31. Dercamp C, Chemin K, Caux C, et al. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory t cells in the inhibition of anti-tumor CD8 T-cell responses. Cancer Res 2005;65:8479.
32. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and antigen-interleukin 10 receptor antibody. J Exp Med 2002;196:541.
33. Cao T, Ueno H, Glaser C, Fay JW, Palucka AK, Banchereau J. Both Langerhans cells and interstitial DC cross-present melanoma antigens and efficiently activate antigen-specific CTL. Eur J Immunol 2007;37:2657.
34. Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 1997;29:545.
35. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654.